WO1996040931A1 - Neutralisation d'epitopes conformationnels du virus de l'anemie infectieuse du poulet - Google Patents
Neutralisation d'epitopes conformationnels du virus de l'anemie infectieuse du poulet Download PDFInfo
- Publication number
- WO1996040931A1 WO1996040931A1 PCT/NL1996/000230 NL9600230W WO9640931A1 WO 1996040931 A1 WO1996040931 A1 WO 1996040931A1 NL 9600230 W NL9600230 W NL 9600230W WO 9640931 A1 WO9640931 A1 WO 9640931A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cav
- vpl
- virus
- neutralizing
- recombinant
- Prior art date
Links
- 241000725585 Chicken anemia virus Species 0.000 title claims abstract description 246
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 83
- 239000013598 vector Substances 0.000 claims abstract description 41
- 241000700605 Viruses Species 0.000 claims abstract description 34
- 229960005486 vaccine Drugs 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 63
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 241000701447 unidentified baculovirus Species 0.000 claims description 37
- 239000002245 particle Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 18
- 101710108545 Viral protein 1 Proteins 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 101000714457 Chaetoceros protobacilladnavirus 2 Capsid protein Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 32
- 239000012634 fragment Substances 0.000 abstract description 13
- 230000001681 protective effect Effects 0.000 abstract description 11
- 230000028993 immune response Effects 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 5
- 229940031626 subunit vaccine Drugs 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 4
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 229940031567 attenuated vaccine Drugs 0.000 abstract 1
- 101710081079 Minor spike protein H Proteins 0.000 description 118
- 102000004169 proteins and genes Human genes 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 34
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 29
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 29
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 29
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 29
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 29
- 241000287828 Gallus gallus Species 0.000 description 28
- 235000013330 chicken meat Nutrition 0.000 description 25
- 230000002238 attenuated effect Effects 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 241000238631 Hexapoda Species 0.000 description 15
- 210000000234 capsid Anatomy 0.000 description 13
- 208000007502 anemia Diseases 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 101710132601 Capsid protein Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101710182846 Polyhedrin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000948165 Milk vetch dwarf virus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009585 enzyme analysis Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101710094856 Apoptin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000006758 Marek Disease Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
- 101710204410 Scaffold protein Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001302800 Beak and feather disease virus Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000702626 Infectious bursal disease virus Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010046862 Vaccination failure Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000003126 immunogold labeling Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16341—Use of virus, viral particle or viral elements as a vector
- C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10061—Methods of inactivation or attenuation
- C12N2750/10062—Methods of inactivation or attenuation by genetic engineering
Definitions
- the present invention provides the formation and characterization of the neutralizing conformational epitope of the CAV protein VPl, which is required for eliciting a protective immune response in vaccinated animals.
- Various vaccine vectors against CAV infections are disclosed. All these vaccines are less pathogenic than CAV. All these vaccine vector are shown to produce the required neutralizing conformational epitope of CAV.
- One vector provides a subunit vaccine, based on a recombinant baculovirus expressing both VPl and VP2 in the same cell.
- a second type of vaccine is a live virus vector, comprising a Marek's disease vector stably harboring the coding sequences for VPl and VP2.
- the third CAV vaccine comprises genetically attenuated CAV strains with a reduced cytopathogenic effect.
- Chicken anemia virus is a small virus of a unique type with a particle diameter of 23 to 25 nm and a genome consisting of a circular single-stranded (minus-strand) DNA (Gelder blom et al., 1989, Noteborn et al., 1991 and Todd et al., 1990). This DNA multiplies in infected cells via a circular double-stranded replicative intermediate, which was recently cloned and fully sequenced. The CAV genome is 2319 nucleotides long (Noteborn and De Boer, 1990). DNA analysis of CAV strains isolated in different continents revealed only minor differences among the various isolates (Meehan et al.
- CAV has been placed into the novel virus family of Circoviridae.
- CAV is not related to the other members of this virus family consisting of animal single-stranded circular-DNA viruses, such as porcine circovirus and psittacine beak-and-feather-disease virus (Noteborn and Koch, 1995) .
- the CAV genome contains one evident promoter/enhancer region (Noteborn et al.
- the major transcript from the CAV genome is an unspliced polycistronic mRNA of about 2100 nucleotides encoding three proteins of 51.6 kDa (VPl), 24.0 kDa (VP2) and 13.3 kDa (VP3 or apoptin (Noteborn and Koch, 1995, Noteborn et al., 1992 and Phenix et al., 1994). All three predicted CAV proteins are synthesi zed in CAV-infected cells (Noteborn and Koch, 1995).
- CAV causes clinical and subclinical disease in chickens, and is recognized as an important avian pathogen worldwide (Mcllroy et al. , 1992 and McNulty et al . , 1991).
- Day-old chicks are especially susceptible to CAV infections.
- anorexia and anemia are observed from 10 days after inoculation with CAV.
- After infection mortality may increase to a maximum of 50%.
- the resistance also increases (Jeurissen et al. , 1992).
- the hematocrit values of chicks that had been infected with CAV at an age of 1-3 days are decreased.
- CAV infections of 1-21 days old chicks result in a depletion of in particular the thymus cortex.
- CAV infection in older chickens can be determined by the occurence of seroconversion.
- the depletion of the cortical thymocytes is considered to cause immunodeficiency resulting in enhanced concurrent infections and to vaccination failures
- CAV-neutralizing antibodies were detected in yolk of eggs produced by hens that had been inoculated with lysates of cells that had been co-infected with CAV-recombinant baculovirus and produced all three CAV proteins, or mainly VPl and VP2. Specific clinical signs did not develop in CAV-challenged progeny that hatched from these eggs (Koch et al. , 1995) .
- the recombinant CAV proteins synthesized by means of the baculovirus expression system can be used as a subunit vaccine.
- the recombinant CAV proteins VPl and VP2 have been proven to protect chicks by maternal immunity (Koch et al, 1995). Since the baculovirus vector is an. insect-specific virus, known to be non-pathogenic for vertebrates, it can be cultured and supplied to chicken without undue risks (Vlak and Keus, 1990) . In general, live-virus vaccines induce a better immune response and are less expensive than sub-unit vaccines.
- CAV or other recombinant-virus vectors such as avian herpes viruses (Nakamura et al. , 1992, Morgan et al., 1993) or fowlpox virus (Nazerian et al. , 1992, Boyle and Heine, 1993).
- avian herpes viruses Nema et al. , 1992, Morgan et al., 1993
- fowlpox virus Newcastle et al. , 1992, Boyle and Heine, 1993.
- These recombinant viruses should express the CAV protein VPl and VP2, in addition to their own proteins, and may be applicable as vaccine for both layer breeders and broiler breeders to protect their offspring against infectious anaemia.
- such vectors may be used to protect maternally immune broilers against subclinical disease.
- the present invention relates to production and analyses of the neutralizing conformational epitope structure of chicken anemia virus (CAV) .
- CAV chicken anemia virus
- neutralizing monoclonal antibodies directed against CAV is disclosed. It is shown that these neutralizing antibodies are directed against a conformational epitope of CAV protein
- VP2 For the formation of the neutralizing conformational epitope of VPl, the synthesis of VP2 within the same cell is required. Recombinant baculovirus expressing only VPl in insect cells only does not react with neutralizing antibodies directed against CAV, but these neutralizing antibodies will react when VPl and VP2 are synthesized in one cell. In purified CAV capsids, however, only VPl is present. This invention discloses that during the synthesis of VPl, and most likely during its complex formation resulting in the CAV capsids, VP2 binds temporarily to VPl. Denaturation of the CAV capsids results in the destruction of the neutralizing epitope, indicating that the neutralizing epitope is an conformational one.
- the invention relates to vaccines and compositions for preventing or treating virus infections in poultry, in particular infections with CAV.
- the invention relates to vaccines that are less pathogenic than the CAV itself but are still capable of producing the neutralizing conformational epitope. Vaccination of chickens with these type of vaccines will lead to the generation of neutralizing antibodies and thus protect the animals and their progeny against CAV infections.
- the invention relates to a baculovirus vector which contains separately on its genome the coding sequences for VPl or VP2. This recombinant baculovirus is able to synthesize VPl and VP2 in the same cell, resulting in the formation of the neutralizing conformational epitope of CAV.
- the invention also relates to the construction of a Marek's " disease virus (MDV) vectors containing CAV sequences encoding VPl, VP2 proteins.
- MDV disease virus
- the invention describes the formation of various attenuated CAV strains, which reveals a reduced cytopathogenic effect in chicken T cells in comparison to a a wild-type-derived CAV strain.
- the attenuated CAV strains were made by introducing point mutations in a cloned CAV DNA genome, in particular a sequence within the promoter/enhancer region has been mutated.
- the attenuated CAV mutant strains are able to produce the neutralizing conformational epitope.
- Processes for the prophylaxis or control of CAV infections, in particular in chickens, and processes for the preparation of recombinant parts of CAV comprising sequences, and processes for the preparation of vaccine are also subjects of the invention.
- reiterating the invention provides a neutralizing antibody or an antibody fragment or derivative thereof reacting with a conformational epitope of viral protein 1 (VPl) of chicken anaemia virus (CAV) recognized by a monoclonal antibody designated as 132-1, 132-2 or 132-3, as produced by the hybridoma's deposited under no. ' s xxxxxx, yyyyyy, zzzzzz at the Insitut Pasteur, Paris, France.
- a workable experiment for determining whether an antibody is an antibody according to the invention is to see if it cross-reacts (or competes) with an antibody from the deposited hybridomas.
- the invention also provides a conformational neutralizing epitope of viral protein 1 of chicken anaemia virus recognized by an antibody as disclosed above.
- the epitope may be part of a larger molecule, it may for instance be bound to a carrier or the epitope may be repeated (at intervals) in a polypeptide chain.
- the epitope is part of a larger part of VPl, because such a molecule will have the right conformation more easily.
- the conformational epitope will only be present on VPl if it is produced in one cell, preferably from one vector together with VP2. Therefore the.
- invention provides a method for producing a viral protein 1 comprising a conformational epitope as disclosed above, comprising the expression of said viral protein 1 in one cell together with viral protein 2 of said CAV whereby the genetic information encoding VPl and the genetic information encoding VP2 are separately present on one recombinant vector.
- the invention also includes vectors for use in a method just described comprising as two separate coding sequences the genetic information encoding VPl and the genetic information encoding VP2.
- a vector is based on Marek' s disease virus vector so that a vaccine can be produced giving protection against two pathogens.
- a very safe and efficient expression system for the viral proteins according to the invention are vectors which are based on a baculo virus vector. As explained before Baculovirus is generally regarded as safe for use in vertebrates since it cannot infect them.
- the invention also provides another way of arriving at vaccines or vaccine components which do have the very important neutralizing comformational epitope, but have reduced pathogenicity.
- a viral protein 1 comprising a neutralizing conformational epitope according to the invention, comprising expressing at least a functional part of VPl and VP2 from genes encoding them, at least one of which genes is under control of a regulatory sequence derived from the CAV sequence upstream of the transcription intitiation site which regulatory sequence is modified to reduce its efficiency.
- a regulatory sequence derived from the CAV sequence upstream of the transcription intitiation site which regulatory sequence is modified to reduce its efficiency.
- virus particles are also part of the invention.
- the modification is preferably in the promoter/enhancer region and most preferably the modification is in the 12 base pair insert in the promoter enhancer region.
- Recombinant virus particles obtainable by any method according to the invention are also part of the invention, as are nucleic acids for use in any method according to the invention, for instance vectors comprising a gene encoding at least a functional part of VPl and a gene encoding a functional part of VP2, at least one of the genes being inder control of a regulatory sequence which is modified to reduce its efficiency.
- the antibodies and epitopes according to the invention are also useful in a diagnostic test kit for detecting or determining the presence of CAV or antibodies to CAV in a sample
- vaccines for the treatment or prophylaxis of CAV associated disease comprising an antibody or an epitope according to the invention together with a suitable adjuvans and/or a suitable vehicle for administration are also provided herewith as are vaccines for the treatment or prophylaxis of CAV associated disease comprising recombinant virus particles according to the invention together with a suitable adjuvans and/or a suitable vehicle for administration.
- mice were injected with purified CAV particles.
- the supernatant of a 1-liter culture of CAV-infected MDCC-MSBl cells was fourty times concentrated by means of a MILLITAN 300-kDa filter (Millipore, USA) .
- the supernatant was dialyzed against lOmM Tris(ph 8.7)-lmM EDTA (TE) buffer.
- TE lOmM Tris(ph 8.7)-lmM EDTA
- SDS sodium dodecyl sulphate
- the CAV capsids were pelleted on a 30% sucrose cushion.
- the pellet containing the CAV capsids was resuspended in 1 ml TE buffer. Mice were twice injected with 100 ⁇ ul CAV-capsid suspension.
- the supernatants of the candidate monoclonal antibodies were diluted 1:2 and then a two-fold dilution series was made.
- the diluted supernatants were incubated for 1 hour with 104-105 TCID50 CAV-Cux-1 (Von Bulow et al., 1983, Von Biilow, 1985).
- TCID50 CAV-Cux-1 Von Bulow et al., 1983, Von Biilow, 1985.
- Approximately one hundred thousand cells of the T cell line MDCC-MSBl transformed by Marek's disease virus were infected with this mixture of diluted supernatant and virus (Yuasa, 1983, Yuasa et al. 1983) .
- Microtiter wells (Greiner, FRG) were coated with the CAV-specific neutralizing monoclonal antibody 132.1, which was 1:10,000 diluted in 50 mM sodiumbicarbonate pH 9.6. Wash the wells three times with tapped water containing 0.05% Tween 80. Saturate the wells with 100 ⁇ ul phosphate-buffered saline containing 4% horse serum, 51 gram/liter NaCl, and 0.05% Tween 80 (saturation buffer) for 30 minutes at 37 * C. Wash the wells three times with tap water containing 0.05% Tween 80.
- the recombinant baculovirus AcRP23-lacZ (Bishop, 1992) was obtained from Dr. R. Possee, NERC Institute of Virology, Oxford, England, and the genomic DNA was purified as described by Summers and Smith (1987).
- Spodoptera frugiperda (Sf9) cell were obtained from the American Tissue Culture Collection (no. CRL 1711) .
- Baculovirus stocks were grown in confluent monolayers and suspension cultures in TC-100 medium (GIBCO/BRL) containing 10% fetal calf serum, as described by Summers and Smith (1987) .
- DNA transformations were carried out in the E.coli strain HB101. All plasmid were multiplied in large culture under agitation, purified on CsCl gradients, and then by filtration over Sephacryl-S500 columns or by filtrations on QIAGEN-chromatography columns.
- Recombinant transfer vector pAcVPl/VP2 DNA was transfected with linearized recombinant baculovirus AcRP23-lacZ DNA, in Sf9 cells. After homologous recombinantion baculoviruses were obtained, which had incorporated in the polyhedrin unit instead of the lacZ the two CAV proteins VPl and VP2 under regulation of the promoter of the plO or polyhedrin gene, respectively.
- the recombinant CAV viruses were characterized for the absence of beta-galactosidase activity in plaques of baculovirus-infected insect cells. Further the integration of CAV DNA sequences in the baculovirus genome was determined by means of a CAV-specific DNA probe in a hybridization experiment.
- I ⁇ rnunop ecipitfltiQn assay Two days after infection, the cells were incubated with Promix label (ICN, USA) and four hours later, the cells were lysed in ElA buffer (50 mM Tris (pH7.5), 0.1% Triton-X-100, 250 mM NaCl, 50 mM NaF, and 5 mM EDTA) and incubated with monoclonal antibody 111.1 directed against VP2 for 2 hours at 4'C, washed with ElA buffer and separated on a PAA-SDS gel.
- ElA buffer 50 mM Tris (pH7.5), 0.1% Triton-X-100, 250 mM NaCl, 50 mM NaF, and 5 mM EDTA
- a CAV-specific serum neutralization test showed that three of these monoclonal antibodies obtained, had a neutralizing activity against CAV. These three CAV-specific neutralizing monoclonal antibodies were called 132.1; 132.2 and 132.3. (deposited under no's xxxx,yyyy, zzzz at the Institut Pasteur, France.
- Electron-microscopic analysis was carried out with purified CAV particles incubated with neutralising antibodies against CAV (132.1) or with monoclonal antibodies 111.1 (against VP2) or 111.3 (against VP3).
- Todd et al. (1990) have reported that purified CAV capsids contain onlya 50-kDa protein, which is most likely VPl.
- the various monoclonal antibodies were detected by immunogold labeling. Only the neutralizing monoclonal antibodies 132.1 were found to bind to CAV particles. Binding of the monoclonal antibody 132.1 to a CAV particle resulted in its lysis.
- CAV capsids which were lysed due to incubation with the neutralising monoclonal antibody 132.1, showed no binding with monoclonal antibo dies directed against VP2 or VP3.
- These results reveal the mechanism by which the neutralizing monoclonal antibodies act: They cause the lysis of the virus capsids, by doing so causing non-infectious particles.
- these data show that purified CAV particles contain (almost) only VPl.
- Neutralizing monoclonal antibodies are directed a ⁇ ainst an conformational epitope on VPl.
- CTB complex-trapping-blocking
- Serum from CAV-infected chickens contains antibodies which will block all epitopes on the CAV " capsids substituteor recombinant VP1/VP2. This means that the CAV capsid or recombinant VP1/VP2 will not bind to the coated monoclonal antibody 132.1. Negative serum, howe ver, will allow binding of CAV capsids or recombinant VP1/VP2 to the coated 132.1. A signal smaller than 0.5 of the signal detected with a negative control serum will be examined as positive.
- the detection level of our CTB-ELISA are titers of 24 to 25 a determined in a serum neutralization test, which is very sensitive. More than 400 sera were analyzed. Comparison to the serum neutralization test revealed that 96.5% of the positive sera within the serum neutrali zation test were positive within the CTB-ELISA, and 98.3% of the negative sera within the serum neutralization test were negative within the CTB-ELISA.
- the coding sequences for the CAV proteins VPl and VP2 were cloned into the baculovirus transfer vector pAcUW51 (cat. no: 21205P) , which was commercially obtained from PharMingen, San Diego, USA.
- This vector is shown in Figure 3 and contains the polyhe drin flanking region, within their midst the baculovirus polyhdrin promoter and the plO promo ter and for both transcription units, the required 3 ' -non-coding transcrioptional sequences including the polyadenylation signals.
- the transfer vector contains prokaryotic sequences for multiplication in bacteria.
- the plasmid pET-16b-VP2 (Noteborn et al.
- This CAV DNA fragment contains the coding region for VP2 flanked by 484 bp 3 ' -non-coding CAV DNA sequences. 106 bp downstream of the start codon for VP2 the start codon for VP3 is found in another reading frame.
- the plasmid pET-16b-VP2 was treated with the restriction enzymes Ndel and Nhel, and the sticky ends were filled by means of Klenow polymerase. A 0.8 kb CAV DNA fragment was isolated.
- the plasmid pAcUW51 was linearized with BamHI, the sticky ends filled by means of Klenow polymerase and finally treated with alkaline phosphatase (CIP) .
- CIP alkaline phosphatase
- the 0.8 kB CAV DNA fragment was ligated at the linearized pAcUW51 DNA.
- the orientation of VP2 in pAcUW51 was determined by restriction enzyme analysis . This construct was called pUW-VP2.
- the plasmid pET-16b-VPl (Noteborn et al., data not published) contains CAV DNA sequences of positions 853 to 2319.
- the CAV DNA insertion contains the complete coding region for the protein VPl flanked by 117 bp 3 ' -non-coding CAV DNA sequences.
- the plasmid pET-16b-VPl was treated with the restriction enzymes Ndel and EcoRI, and the sticky ends were filled by means of Klenow polymerase. A 1.45 kb CAV DNA fragment was isolated.
- the plasmid pUW-VP2 was linearized by EcoRI, the sticky ends filled by means of Klenow polymerase and finally treated by CIP.
- the 1.45 kb CAV DNA fragment was ligated at the linearized pUW-VP2.
- the orientation of VPl opposite of the plO promoter unit was determined by restriction-enzyme analysis, and the final construct pAcVPl/VP2 is shown in Figure 3.
- the open reading frames encoding VPl and VP2 were separately cloned into a single baculovirus transfervector, viz pAcUW51.
- the CAV sequences encoding VPl are under the regulation of the baculovirus plO promoter and VP2 under the regulation of the baculovirus poyhedrin promoter.
- Transfection of Sf9 insect cells occurred with 'naked' baculovirus DNA and transfervector DNA.
- homologous recombinantion baculovirues were obtained which had incorporated the VP1/VP2 expression unit, integrated in the polyhedrin region of the recombinant baculovirus, instead of the lacZ unit.
- the recombinant baculoviruses were characterized for the absence of beta-galactosidase activity and integration of CAV DNA sequences.
- CAV-specific products could be detected as radioactively labeled protein band or Coomassie-brilliant blue stained protein band. The latter result indicates that both products are produced in relatively high levels in recombi nant-VPl/VP2-baculovirus-infected insect cells. Sf9 cells infected with a recombinant-lacZ baculovirus did not contain these CAV-specific proteins.
- VP2 is a non-structural protein that at some stage of infection is required for virus assembly and/or the correct conformation of VPl, which result(s) in the formation of the neutralizing epitope(s).
- VP2 acts as a scaffold protein that is necessary during the assembly of the virion but absent in the final product (Leibowitz and Horwitz, 1975) .
- scaffold proteins are the IVa2 and 39kDa proteins of adenovirus (D'Halluin et al. , 1978; Persson et al., 1979). These proteins act as scaffolds for the formation of the so-called light capsid, but are removed in the next step.
- VP2 might function in a similar way during the formation of CAV virions. However, at this stage, we cannot entirely exclude that (very) small amounts of VP2 that remained undetected in electroblots of purified CAV preparations (Todd et al.
- VPl and VP2 interact temporarily with each other.
- the neutralizing epitope of VPl is only formed when VP2 is present, and therefore is a conformationally distinct epitope. This implies that VPl and VP2 associate with each other during a short time period.
- Sf9 insect cells were infected with recombinant baculoviruses, which synthesized VPl, VP2, or VPl plus VP2.
- the recombinant CAV products which will be used for vaccination of laying-hens, can be synthesized by means of the baculovirus system.
- the CAV proteins can also be. synthesized by means of other expression systems, such as yeast cells, via (retro)- viral infection or gene amplification (CHO-dhfr system) in mammalian cell systems.
- the expression of fragments of VPl in combination with VP2 or VP2 and VP3 may be sufficient for the induction of a protective immune response.
- VPl, VP2 or VP3, separately, but then within the context of a living virus vector, is also suitable for the induction of a protective immune response against CAV infections.
- the expression of fragments of one of the abo ve-mentioned CAV proteins by living virus vectors may be sufficient for the induction of a protective immune response.
- VP3 causes apoptosis in, i.e. chicken mononuclear cells (PCT/NL94/00168; Noteborn et al. , 1994a) favors to construct living virus vectors not expres sing VP3.
- the replication of i.e. Marek_s disease virus might be negatively influenced by VP3-induced apoptosis.
- recombinant-VPl/VP2 MDV Construction of recombinant-VPl/VP2 MDV.
- recombinant transfer vector pMD-US10-SV-VPl/VP2 DNA was transfected with MDV (Rispens isolate) DNA, in CEF cells.
- MDV Rospens isolate
- recombinant MDVs were obtained, which had incor porated the CAV coding sequences in the the US10 region (Nakamura et al. , 1992).
- the recombinant-VPl/VP2 MDVs were characterized for the presence of the expression of VP2.
- in-parallel plaque purification and immuno-peroxidase analyis using a monoclonal antibody directed against VP2 several 100%-purified recombinant-VPl/VP2 MDV independent strains were obtained.
- the monoclonal antibody 132.1 is directed against a neutralizing epitope of VPl.
- the CAV-EcoRI clone is used for the production of viable infectious CAV particles.
- the complete CAV insert the 2,319-bp EcoRI fragment has to be isolated from the bacterial sequences and recircularized by DNA polymerase treatment.
- MDCC-MSBl cells are transfected with the recircularized EcoRI fragments and after several days wild-type CAV will be produced.
- wild-type CAV in principle one can produce mutant CAV and if the mutant is less pathogenic, attenuated CAV.
- the complete strategy for the production of attenuated CAV is shown in Figure 5.
- CAV genomes containin ⁇ mutated promo er/enh ncer regions
- a remarkable feature of the CAV promoter/enhancer region is a sequence of 4 or 5 near-perfect 21-bp repeats, interrupted by an insert of 12-bp (Noteborn et al. , 1991). This region is involved in the regulation of the CAV transcription (Noteborn et al., 1994b).
- For the production of attenuated CAV we have introduced mutational changes in the 12-bp insert/direct-repeat region of the CAV-EcoRI clone (Noteborn et al. , 1991).
- the mutated promoter/enhancer region of the wild-type (wt) and the various CAV mutants are shown in Fig. 6.
- the Nae-mutant contains no
- All other mutants contain 4 original direct repeats instead of 5, as is the case for the CAV-EcoRI clone.
- the various CAV mutants called '6b'p, '12bp', '24bp' contain changed 12-bp inserts.
- the CAV mutants * 6bp' , '12bp' , '18bp', '24bp' and 'wt in Nae' contain all additional sequences flanking the 12-bp insert/direct-repeat region.
- the linker 5' -GCCCATGT-3 ' and at the 3 '-site the linker 5 ' -GATCCGCC-3 ' has been introduced.
- VP3 To determine whether the mutated CAV genomes could produce live CAV particles, firstly the synthesis of VP3 was examined. At several timepoints after transfection, a part of the various transfected MDCC-MSBl-cell cultures were aceton-fixed and analysed by indirect immunofluorescence using a monoclonal antibody directed against VP3. In parallel, 1 ml of each culture was added to 9 ml of fresh RPMI-medium, which was supplemented with 10% fetal bovine serum. Approximately 15% and 90% of the cultured MDCC-MSBl cells, transfected with 'wt' recircularized CAV genome DNA, contained VP3 after 6 days and 11 days (the cells were one time passaged after transfection), respectively.
- the CAV mutant genome 'Nae' lacking the complete 12-bp insert/direct-repeat region, was shown not to produce infectious virus particles.
- a similar percentage is obtained with expression plasmid pRSV-VP3 (Noteborn et al . , 1994b) encoding VP3 only, and which are known not to replicate in eukaryotic cells. After 3 weeks and several passages, no VP3 was present anymore in the Nae-DNA transfected MDCC-MSBl cell cultures.
- CAV mutants have a reduced cytopat oqenic effect.
- the transfected cells were analysed whether they had become apoptotic.
- CAV is known to induce apoptosis, 2-3 days after infection.
- the cells were stained with propidium iodide, which stains 'normal' DNA strongly, but apoptotic DNA weakly and/or irregularly.
- PMC-MSBl cells transfected with 'wt' DNA were shown to be apoptotic, whereas the majority of the cells, transfected with the various mutated CAV-DNA genome were not.
- the capacity for inducing apoptosis was shown to be mostly reduced for the CAV mutants ' 6bp' and '18bp' .
- Attenuated CAV synthesizes the CAV-specific neutralizing epitope-
- Figure 1 shows the pepscan analysis of the neutralizing monoclonal antibodies of type 132.1 with peptides (12-mers) derived from VPl.
- Figure 2 shows the pepscan analysis of the neutralizing monoclonal antibodies of type 132.1 with peptides (12-mers) derived from VP2.
- Figure 3 shows the diagrammatic representation of the recombinant transfer pUW-VPl/VP2.
- Figure 4 shows the diagrammatic representation of the recombinant transfer vector pMD-US10-SV-VPl/VP2..
- Figure 5 shows the strategy for the production of attenuated CAV-mutants, based on the plasmid pCAV/EcoRl containing 2319 bp of wild-type CAV.
- Figure 6 shows the schematic structure of the CAV promoter/enhancer region of the various mutated and wild-type CAV strains .
- Figure 7 shows the VP3-expression rates obtained for the various mutant-CAVs and wild-type CAV after tranfection of mutant or wild-type circularized DNA.
- the VP3-expression rate are given as percentage of VP3-positive MDCC-MSBl cells.
- FIG. 8 gives the sequence of CAV.
- CAV chicken anemia virus
- ORF-3 gene and the development of an ELIA for the detection of serum antibody to CAV.
- Anaemia-dermatitis of broilers field observations on its occurrence, transmission and prevention. Avian Pathology 17, 113-120.
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59137/96A AU720640B2 (en) | 1995-06-07 | 1996-06-07 | Neutralizing conformational epitopes of chicken anemia virus |
NZ309172A NZ309172A (en) | 1995-06-07 | 1996-06-07 | Neutralizing conformational epitopes of chicken anemia virus |
EP96916379A EP0832242A1 (fr) | 1995-06-07 | 1996-06-07 | Neutralisation d'epitopes conformationnels du virus de l'anemie infectieuse du poulet |
JP9500328A JPH11510367A (ja) | 1995-06-07 | 1996-06-07 | ニワトリ貧血ウイルスの中和性立体配座エピトープ |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/480,020 US5932476A (en) | 1990-09-12 | 1995-06-07 | Cloning of chicken anemia virus DNA |
US08/480,020 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996040931A1 true WO1996040931A1 (fr) | 1996-12-19 |
Family
ID=23906352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL1996/000230 WO1996040931A1 (fr) | 1995-06-07 | 1996-06-07 | Neutralisation d'epitopes conformationnels du virus de l'anemie infectieuse du poulet |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0832242A1 (fr) |
JP (1) | JPH11510367A (fr) |
CN (1) | CN1194001A (fr) |
AU (1) | AU720640B2 (fr) |
CA (1) | CA2221570A1 (fr) |
NZ (1) | NZ309172A (fr) |
WO (1) | WO1996040931A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029717A2 (fr) * | 1997-12-11 | 1999-06-17 | University Of Saskatchewan | Virus porcins du syndrome de deperissement multisystemique apres sevrage |
WO2002102999A1 (fr) * | 2001-06-14 | 2002-12-27 | The University Of Melbourne | Circovirus attenue |
EP1610757A2 (fr) * | 2003-04-10 | 2006-01-04 | Transform Pharmaceuticals, Inc. | Profilage de variants conformationnels, compositions anticorps et procedes d'utilisation associes |
US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US7390494B2 (en) | 1997-12-05 | 2008-06-24 | Wyeth | Circovirus sequences associated with piglet weight loss disease (PWD) |
US9987348B2 (en) | 2013-09-25 | 2018-06-05 | Zoetis Services Llc | PCV2B divergent vaccine composition and methods of use |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001275664A (ja) * | 2000-02-29 | 2001-10-09 | Akzo Nobel Nv | 低い病原性のニワトリ貧血ウイルス |
CN113897356B (zh) * | 2021-10-20 | 2024-04-30 | 佛山科学技术学院 | 一种检测鸡传染性贫血病毒荧光定量pcr试剂盒及引物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0473210A2 (fr) * | 1990-07-30 | 1992-03-04 | Akzo Nobel N.V. | Virus recombinant de la maladie de Marek |
WO1992004446A1 (fr) * | 1990-09-12 | 1992-03-19 | Aesculaap B.V. | Clonage de l'adn du virus de l'anemie aviaire |
EP0483911A2 (fr) * | 1990-10-31 | 1992-05-06 | Akzo N.V. | Vaccin et diagnostic concernant le virus de l'anémie des poulets |
WO1995003414A2 (fr) * | 1993-07-20 | 1995-02-02 | Aesculaap B.V. | Mutants et vaccins du virus de l'anemie infectieuse du poulet et utilisations basees sur les proteines virales vp1, vp2 et vp3 ou des sequences de ce virus assurant leur codage |
-
1996
- 1996-06-07 WO PCT/NL1996/000230 patent/WO1996040931A1/fr not_active Application Discontinuation
- 1996-06-07 NZ NZ309172A patent/NZ309172A/xx unknown
- 1996-06-07 CN CN96195434A patent/CN1194001A/zh active Pending
- 1996-06-07 EP EP96916379A patent/EP0832242A1/fr not_active Withdrawn
- 1996-06-07 CA CA002221570A patent/CA2221570A1/fr not_active Abandoned
- 1996-06-07 JP JP9500328A patent/JPH11510367A/ja active Pending
- 1996-06-07 AU AU59137/96A patent/AU720640B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0473210A2 (fr) * | 1990-07-30 | 1992-03-04 | Akzo Nobel N.V. | Virus recombinant de la maladie de Marek |
WO1992004446A1 (fr) * | 1990-09-12 | 1992-03-19 | Aesculaap B.V. | Clonage de l'adn du virus de l'anemie aviaire |
EP0483911A2 (fr) * | 1990-10-31 | 1992-05-06 | Akzo N.V. | Vaccin et diagnostic concernant le virus de l'anémie des poulets |
WO1995003414A2 (fr) * | 1993-07-20 | 1995-02-02 | Aesculaap B.V. | Mutants et vaccins du virus de l'anemie infectieuse du poulet et utilisations basees sur les proteines virales vp1, vp2 et vp3 ou des sequences de ce virus assurant leur codage |
Non-Patent Citations (5)
Title |
---|
G. KOCH ET AL.: "Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus.", VACCINE, vol. 13, no. 8, June 1995 (1995-06-01), GUILDFORD, GB, pages 763 - 770, XP002013395 * |
M. MCNULTY ET AL.: "Production and preliminary characterization of monoclonal antibodies to chicken anemia agent.", AVIAN DISEASES, vol. 34, no. 2, April 1990 (1990-04-01), COLLEGE STATION, TX, USA, pages 352 - 358, XP000577479 * |
M. NOTEBORN ET AL.: "Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle.", JOURNAL OF VIROLOGY, vol. 65, no. 6, June 1991 (1991-06-01), BALTIMORE, MD, USA, pages 3131 - 3139, XP002013394 * |
M. NOTEBORN ET AL.: "Chicken anaemia virus infection: molecular basis of pathogenicity.", AVIAN PATHOLOGY, vol. 24, no. 1, 1995, HOUGHTON, GB, pages 11 - 31, XP000577477 * |
M. NOTEBORN ET AL.: "Identification of the promoter region of chicken anemia virus (CAV) containing a novel enhancer-like element.", GENE, vol. 150, no. 2, 1994, AMSTERDAM, THE NETHERLANDS, pages 313 - 318, XP002013393 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7803613B2 (en) | 1997-10-03 | 2010-09-28 | Merial Sas | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US7833783B2 (en) | 1997-10-03 | 2010-11-16 | Merial Sas | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US7803926B2 (en) | 1997-10-03 | 2010-09-28 | Merial Sas | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US7504206B2 (en) | 1997-10-03 | 2009-03-17 | Merial Sas | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US10052375B2 (en) | 1997-12-05 | 2018-08-21 | Zoetics Services LLC | Circovirus sequences associated with piglet weight loss disease (PWD) |
US7425444B2 (en) | 1997-12-05 | 2008-09-16 | Wyeth | Circovirus sequences associated with piglet weight loss disease (PWD) |
US7390494B2 (en) | 1997-12-05 | 2008-06-24 | Wyeth | Circovirus sequences associated with piglet weight loss disease (PWD) |
US7405075B2 (en) | 1997-12-05 | 2008-07-29 | Wyeth | Circovirus sequences associated with piglet weight loss disease (PWD) |
US9717784B2 (en) | 1997-12-05 | 2017-08-01 | Zoetis Services Llc | Circovirus sequences associated with piglet weight loss disease (PWD) |
US9700613B2 (en) | 1997-12-05 | 2017-07-11 | Zoetis Services Llc | Circovirus sequences associated with piglet weight loss disease (PWD) |
US8916353B2 (en) | 1997-12-05 | 2014-12-23 | Zoetis W Llc | Circovirus sequences associated with piglet weight loss disease (PWD) |
US7407803B2 (en) | 1997-12-05 | 2008-08-05 | Wyeth | Circovirus sequences associated with piglet weight loss disease (PWD) |
US7604808B2 (en) | 1997-12-05 | 2009-10-20 | Wyeth | Circovirus sequences associated with piglet weight loss disease (PWD) |
US7741039B2 (en) | 1997-12-11 | 2010-06-22 | Merial Sas | Postweaning multisystemic wasting syndrome virus from pigs |
WO1999029717A2 (fr) * | 1997-12-11 | 1999-06-17 | University Of Saskatchewan | Virus porcins du syndrome de deperissement multisystemique apres sevrage |
WO1999029717A3 (fr) * | 1997-12-11 | 1999-10-07 | Univ Saskatchewan | Virus porcins du syndrome de deperissement multisystemique apres sevrage |
US7144698B2 (en) | 1997-12-11 | 2006-12-05 | Merial Sas | Postweaning multisystemic wasting syndrome virus from pigs |
WO2002102999A1 (fr) * | 2001-06-14 | 2002-12-27 | The University Of Melbourne | Circovirus attenue |
US7442378B2 (en) | 2001-06-14 | 2008-10-28 | The University Of Melbourne | Attenuated circovirus |
EP1610757A2 (fr) * | 2003-04-10 | 2006-01-04 | Transform Pharmaceuticals, Inc. | Profilage de variants conformationnels, compositions anticorps et procedes d'utilisation associes |
EP1610757A4 (fr) * | 2003-04-10 | 2007-05-30 | Transform Pharmaceuticals Inc | Profilage de variants conformationnels, compositions anticorps et procedes d'utilisation associes |
US9987348B2 (en) | 2013-09-25 | 2018-06-05 | Zoetis Services Llc | PCV2B divergent vaccine composition and methods of use |
Also Published As
Publication number | Publication date |
---|---|
NZ309172A (en) | 1999-11-29 |
CN1194001A (zh) | 1998-09-23 |
AU720640B2 (en) | 2000-06-08 |
CA2221570A1 (fr) | 1996-12-19 |
JPH11510367A (ja) | 1999-09-14 |
EP0832242A1 (fr) | 1998-04-01 |
AU5913796A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Koch et al. | Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus | |
Noteborn et al. | Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle | |
RU2389506C2 (ru) | Вакцина против рсv-2 | |
M. Noteborn et al. | Chicken anaemia virus infection: molecular basis of pathogenicity | |
EP0554414B1 (fr) | Procede de production d'un vaccin sous-unitaire contre le parvovirus canin et autres virus apparentes | |
Yao et al. | Induction of apoptosis in vitro by the 17-kDa nonstructural protein of infectious bursal disease virus: possible role in viral pathogenesis | |
Neubauer et al. | Analysis of the contributions of the equine herpesvirus 1 glycoprotein gB homolog to virus entry and direct cell-to-cell spread | |
EP1253201B1 (fr) | Mutants et vaccins de l'anémie infectieuse du poulet et utilisations basées sur la protéine VP3 ou des séquences de ce virus assurant leur codage | |
CA2091181C (fr) | Clonage de l'adn du virus de l'anemie infectieuse du poulet | |
HUT62325A (en) | Chicken anaemia virus vaccine and diagnostic | |
AU720640B2 (en) | Neutralizing conformational epitopes of chicken anemia virus | |
US6071520A (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor | |
Ghiasi et al. | Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection | |
US20020119527A1 (en) | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines | |
US6217870B1 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor | |
US20050100552A1 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor | |
US5789567A (en) | Chicken infectious anemia virus vaccine | |
MXPA97009851A (en) | Epithopes conformational neutralizers of poem anemia viruses | |
WO1996001116A9 (fr) | Vaccin contre le virus de l'anemie infectieuse du poulet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96195434.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2221570 Country of ref document: CA Ref document number: 2221570 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996916379 Country of ref document: EP Ref document number: 309172 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 1997 500328 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/009851 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1996916379 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996916379 Country of ref document: EP |